For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
Citation
Think Tank: More FDA 510(k) Oversight Needed, Driving Innovation Overseas
Citation
Competitive Enterprise Institute Criticizes the FDA
Citation
Conservative think tank report blasts FDA
Citation
News Bites: Bachmann’s IPAB Claims Fall Flat
News Release
New Study Reveals Mismanagement of FDA Medical Device Reviews
Washington, D.C., October 12, 2011—The Food and Drug Administration’s 510(k) review process for medical devices has been severely mismanaged by agency officials, according to…
Study
Stifling Medical Device Innovation
The United States has long been the home to cutting-edge innovations in the medical device industry. However, increasingly burdensome regulatory policy is driving pioneering research…